Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Why & What of the ACR’s Clinical Practice Guidelines

Ruth Jessen Hickman, MD  |  Issue: February 2018  |  February 18, 2018

This issue of having relatively lesser amounts of level A evidence is not limited to rheumatology, but affects other specialties as well. For example, the levels of evidence available to rheumatologists are roughly equivalent to the levels of evidence available to be used in infectious disease and kidney guidelines.14-15 In other specialties, such as cardiovascular disease, this may be less of a problem, because they often get more research funding.

“It’s not shocking that in a medical discipline that addresses rare diseases and has limited public funding that you’re not going to have predominantly level A evidence—and it’s not unique either,” explains Dr. Caplan. “The same could be said of all medical care—particularly subspecialty care—that you never have the evidence base that you’d like.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Ideally, the process of guideline formation itself could be used to help shape the research agenda, & guidelines do usually contain recommendations for future research.

Improving the Evidence Base

The broader question remains as to how the evidence base for the guidelines might be improved through greater research. Although RCTs remain unrealistic in many scenarios in rheumatology, an improvement in the number of high-quality observational studies could also help improve the evidence base. In many cases, registry data may be studied, such as were used in analyses of ankylosing spondylitis patients switching TNF-α inhibitor therapy as part of routine clinical care.19

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Ideally, the process of guideline formation itself could be used to help shape the research agenda, and guidelines do usually contain recommendations for future research. But Dr. Neogi notes that companies are usually not interested in funding studies that will not influence whether or not their product will be used. She also notes that commercial companies are not typically interested in funding needed studies that may determine the optimal use of older, existing generic drugs.

She adds, “This has to be a priority for NIH and other funding sources. Yes, our hands are tied, because this is the evidence that is out there. It’s a call to action to see if we can convince funders to help us address these important questions.” She believes that the state of treatment guidelines in rheumatology regarding the level of evidence is simply reflective of what investigators, funders and industry have deemed important to study in RCTs. She notes, “Rheumatologic diseases have a big impact on people’s lives, and yet the funding by a variety of different organizations does not adequately reflect the public health burden of these diseases.”

Future Guidelines

Guidelines need to be updated as new data become available. Currently, the ACR employs a system of evaluating the medical literature every 12 months to see if a guideline update is warranted.

Page: 1 2 3 4 5 6 7 8 9 10 | Single Page
Share: 

Filed under:Practice Support Tagged with:Clinical Practice GuidelinesThe American College of Rheumatology

Related Articles
    Dr. Caplan turned 106 on Nov. 21 and remains physically and mentally active.

    Paul S. Caplan, MD: A Physician’s Journey

    March 8, 2020

    Editor’s note: It is with much sadness that we learned this morning that Paul Caplan, MD, passed away yesterday, March 7, 2020. “He was a remarkable person who continued to celebrate life up to the end,” says Terence W. Starz, MD, University of Pittsburgh School of Medicine. “He had a great caring, wisdom, and commitment…

    Alisusha; Trueffelpix / shutterstock.com

    3 New Vasculitis Guidelines Discussed

    May 13, 2021

    The ACR, in concert with the Vasculitis Foundation, released three new vasculitis guidelines online first in July, with a fourth slated for publication by the end of the year. These are the first ever to be produced and endorsed by the ACR and the Vasculitis Foundation. Although most of the recommendations are conditional, due to…

    Vasculitis Guidelines in Focus, Part 6: Giant Cell Arteritis

    September 27, 2022

    In 2021, the ACR—in concert with the Vasculitis Foundation (VF)—released four new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis (GCA) and Takayasu arteritis, 3) polyarteritis nodosa and 4) Kawasaki disease. The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June…

    Updated Perioperative Guideline Released: Recommendations Balance Risks of Infection & Disease Flare

    September 13, 2022

    The 2017 recommendations are updated to reflect changes in medical literature, as well as to include newly approved drugs.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences